期刊
ONCOIMMUNOLOGY
卷 10, 期 1, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2021.1971430
关键词
Small-cell lung cancer; OX40; CD4; CD8; survival
资金
- Department of Translational Pathology, Hokkaido University Graduate School of Medicine
- Center for Respiratory Diseases, JCHO Hokkaido Hospital
- Department of Pulmonary Medicine, Fukushima Medical University
- Department of Respiratory Medicine, Hokkaido Cancer Center
In small-cell lung cancer (SCLC), high infiltration of OX40(+) lymphocytes in tumor stroma is associated with better survival outcomes compared to low infiltration, suggesting a potential role for OX40(+) lymphocytes in regulating relapse. Coordinating the recruitment of OX40(+) lymphocytes with CD4(+) and CD8(+) T cells in tumor stroma may be a promising immunotherapeutic strategy for SCLC patients.
OX40 (CD134) is a co-stimulatory molecule mostly expressed on activated T lymphocytes. Previous reports have shown that OX40 can be an immuno-oncology target and a clinical biomarker for cancers of various organs. In this study, we collected formalin-fixed paraffin-embedded tumor samples from 124 patients with small-cell lung cancer (SCLC) who had undergone surgery. We analyzed the expression profiles of OX40 and other relevant molecules, such as CD4, CD8, and Foxp3, in tumor stroma and cancer nest using immunohistochemistry and investigated their association with survival. High infiltration of OX40(+) lymphocytes (OX40(high)) in tumor stroma was positively associated with relapse-free survival (RFS) and overall survival (OS) compared with low infiltration of OX40(+) lymphocytes (OX40(low)) (RFS, median, 26.0 months [95% confidence interval (CI), not reached (NR)-NR] vs 13.2 months [9.1-17.2], p = .024; OS, NR [95% CI, NR-NR] vs 29.8 months [21.3-38.2], p = .049). Multivariate analysis revealed that OX40(high) in tumor stroma was an independent indicator of prolonged RFS. Moreover, RFS of patients with OX40(high)/CD4(high) in tumor stroma was significantly longer than that of patients with OX40(low)/CD4(low). The RFS of patients with tumor stroma with OX40(high)/CD8(high) was significantly longer than that of patients with tumor stroma with OX40(low)/CD8(high), OX40(high)/CD8(low), or OX40(low)/CD8(low). These findings suggest that OX40(+) lymphocytes in tumor stroma play a complementary role in regulating the relapse of early-stage SCLC. Reinforcing immunity by coordinating the recruitment of OX40(+) lymphocytes with CD4(+) and CD8(+) T cells in tumor stroma may constitute a potential immunotherapeutic strategy for patients with SCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据